CD276 Antibodies

Structure of CD276

CD276 (B7-H3) is a type I transmembrane glycoprotein. Its molecular weight varies among different species, mainly due to the different degrees of gene splicing and glycosylation modification.

This protein is composed of 316 amino acids (taking human 4Ig-B7-H3 as an example), and its extracellular segment contains immunoglobulin-like domains (IgV and IgC). These domains form stable dimers through disulfide bonds, which form the basis of interaction with ligands. Its intracellular segment is relatively short and lacks known clear signaling motifs. This feature suggests that it may transmit immunosuppressive signals by forming complexes with other membrane proteins. The hydrophobic α -helix in the transmembrane region is responsible for anchoring proteins to the cell membrane. Its complex N-link glycosylation modification not only affects the molecular weight of the protein, but also directly participates in regulating its specificity and affinity for binding to receptors.

Fig. 1 Structure of B7-H3 Protein.¹

Key structural properties of CD276:

• Extracellular immunoglobulin-like domain (IgV-IgC)
• Homodimer configuration stabilized by disulfide bonds
• Highly glycosylated immunomodulatory interface

Functions of CD276

The main function of CD276 (B7-H3) is to act as a regulatory molecule in immune responses. However, its specific effects are environmentally dependent and show significant differences under physiological and pathological conditions.

The interaction between CD276 and its ligands does not follow the typical affinity saturation model, but rather exhibits complex concentration dependence and microenvironment sensitivity, which reflects its functional plasticity in immune synapses and the complexity of regulation as an immune checkpoint molecule.

Applications of CD276 and CD276 Antibody in Literature

1. Zhou, Wu-Tong, and Wei-Lin Jin. "B7-H3/CD276: an emerging cancer immunotherapy." Frontiers in immunology 12 (2021): 701006. https://doi.org/10.3389/fimmu.2021.701006

The article indicates that CD276 (B7-H3) is an immunomodulatory protein of the B7 family, which is highly expressed in various tumors and participates in the regulation of the tumor microenvironment. It is a potential target for cancer immunotherapy. Multiple therapies based on CD276 have demonstrated good anti-tumor effects and safety in preclinical studies.

2. Cheng, Maosheng, et al. "CD276-dependent efferocytosis by tumor-associated macrophages promotes immune evasion in bladder cancer." Nature Communications 15.1 (2024): 2818. https://doi.org/10.1038/s41467-024-46735-5

This study reveals that CD276 is expressed on tumor-associated macrophages (Tams), promoting their cell burial by activating JUN transcription factors, thereby inhibiting T cell infiltration and weakening anti-tumor immunity. Combined blocking of CD276 and PD-1 can significantly inhibit tumor growth, providing a new target for combined immunotherapy.

3. Getu, Ayechew Adera, et al. "New frontiers in immune checkpoint B7-H3 (CD276) research and drug development." Molecular Cancer 22.1 (2023): 43. https://doi.org/10.1186/s12943-023-01751-9

This study reveals that CD276 (B7-H3) is specifically highly expressed in tumors. Besides its immune checkpoint function, it also drives malignant processes such as tumor proliferation, metastasis and metabolic reprogramming. Its significantly different expression pattern from normal tissues makes it a highly potential anti-cancer target. Recent research has made significant progress in both the mechanism of action and drug development.

4. Feng, Yang, et al. "Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability." Cell reports 42.12 (2023). https://doi.org/10.1016/j.celrep.2023.113503

This study reveals that for the CD276 target, researchers have developed a novel antibody-drug conjugate, m276-SL-PBD. This drug, through multiple optimizations, can efficiently eliminate large triple-negative breast cancer tumors at extremely low doses. Its therapeutic index has significantly improved compared to previous generations of drugs, providing a promising targeted solution for the treatment of various solid tumors.

5. Liu, Shengzhuo, et al. "The role of CD276 in cancers." Frontiers in Oncology 11 (2021): 654684. https://doi.org/10.3389/fonc.2021.654684

The article indicates that CD276 (B7-H3) is an abnormally expressed immune checkpoint molecule in malignant tumors, which drives tumor progression by promoting tumor cell proliferation, invasion and migration. Existing evidence indicates that the therapeutic strategy targeting CD276 shows great therapeutic potential in malignant tumors.

Creative Biolabs: CD276 Antibodies for Research

Creative Biolabs specializes in the production of high-quality CD276 antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom CD276 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our CD276 antibodies, custom preparations, or technical support, contact us at email.